Malaria Treatment Policy Change and Implementation: The Case of Uganda

Abstract

Malaria due to P. falciparum is the number one cause of morbidity and mortality in Uganda where it is highly endemic in 95% of the country. The use of efficacious and effective antimalarial medicines is one of the key strategies for malaria control. Until 2000, Chloroquine (CQ) was the first-line drug for treatment of uncomplicated malaria in Uganda. Due to progressive resistance to CQ and to a combination of CQ with Sulfadoxine-Pyrimethamine, Uganda in 2004 adopted the use of ACTs as first-line drug for treating uncomplicated malaria. A review of the drug policy change process and postimplementation reports highlight the importance of managing the policy change process, generating evidence for policy decisions and availability of adequate and predictable funding for effective policy roll-out. These and other lessons learnt can be used to guide countries that are considering anti-malarial drug change in future.

DOI: 10.4061/2011/683167

Extracted Key Phrases

3 Figures and Tables

Statistics

02040201220132014201520162017
Citations per Year

58 Citations

Semantic Scholar estimates that this publication has 58 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@inproceedings{Nanyunja2011MalariaTP, title={Malaria Treatment Policy Change and Implementation: The Case of Uganda}, author={Miriam Nanyunja and Juliet Nabyonga Orem and Frederick Kato and Mugagga Kaggwa and Charles Katureebe and Joaquim Saweka}, booktitle={Malaria research and treatment}, year={2011} }